Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11992930 | 0.91 | SCN9A (0.45) | SCN9AFPR2TDP1P2RX3P2RY1 | |
| SCHEMBL11922572 | 0.90 | FPR2 (0.48) | SCN9AFPR2TDP1P2RX3P2RY1 | |
| SCHEMBL11991467 | 0.87 | SCN9A (0.44) | SCN9AFPR2TDP1P2RX3P2RY1 | |
| SCHEMBL11991469 | 0.86 | SCN9A (0.43) | SCN9AFPR2TDP1P2RX3P2RY1 | |
| SCHEMBL11991519 | 0.85 | KMT2A (0.35) | SCN9AFPR2 | |
| SCHEMBL12303669 | 0.84 | P2RY1 (0.44) | SCN9AFPR2TDP1P2RY1DRD1 | |
| SCHEMBL12303674 | 0.82 | P2RY1 (0.48) | SCN9AFPR2TDP1P2RY1DRD1 | |
| SCHEMBL11991472 | 0.82 | KMT2A (0.34) | SCN9AFPR2P2RX3KCNH2 | |
| SCHEMBL11991583 | 0.81 | SCN9A (0.40) | SCN9AFPR2TDP1P2RX3P2RY1 | |
| SCHEMBL12763926 | 0.80 | TDP1 (0.44) | SCN9AFPR2TDP1P2RX3P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912182-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8541402-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | SCN9A 2294/4885FPR2 3185/4885TDP1 1659/4885 |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | SCN9A 2294/4885FPR2 3185/4885TDP1 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.